Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PIK3CA H1047R
i
Other names:
PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5290
Related biomarkers:
Expression
Mutation
CNA
Others
‹
PIK3CA mutation (108)
PIK3CA E545K (26)
PIK3CA E542K (10)
BRAF V600E + PIK3CA mutation (4)
EGFR mutation + PIK3CA mutation (4)
PIK3CA E545 (4)
PIK3CA H1047 (4)
PIK3CA K111N (4)
PIK3CA E542 (3)
PIK3CA E546 (3)
PIK3CA H1047L (3)
PIK3CA M1043I (3)
PIK3CA mutation + PTEN mutation (3)
PIK3CA wild-type (3)
EGFR T790M + PIK3CA H1047R (2)
ER negative + PIK3CA H1047R (2)
HER-2 V777L + PIK3CA H1047R (2)
PIK3CA C420R (2)
PIK3CA E545A (2)
PIK3CA N345K (2)
PIK3CA Q75E (2)
PIK3CA mutation + ESR1 mutation (2)
PIK3CA mutation + KRAS mutation (2)
TP53 T175H + PIK3CA H1047R (2)
TP53 mutation + PIK3CA mutation + CD74 mutation (2)
ALK rearrangement + PIK3CA mutation (1)
ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation (1)
EGFR L858R + PIK3CA H1047R + PIK3CA E545K (1)
EGFR T790M + PIK3CA Mutation (1)
EGFR exon 19 mutation + EGFR C797S + PIK3CA mutation (1)
HR positive + PIK3CA H1047R (1)
HR positive + PIK3CA H1047R + ER D538G (1)
HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G (1)
IDH1 R132C + PIK3CA E545K + IDH2 R172K (1)
PIK3CA D350G (1)
PIK3CA E110K (1)
PIK3CA E453K (1)
PIK3CA E542Q (1)
PIK3CA E545G (1)
PIK3CA E545X (1)
PIK3CA G1049R (1)
PIK3CA G1049R + AKT1 E17K (1)
PIK3CA G106_108del (1)
PIK3CA H1047R + PIK3CA D959N + ER E380Q (1)
PIK3CA H1047X (1)
PIK3CA I391M (1)
PIK3CA K944N (1)
PIK3CA K966E (1)
PIK3CA N345K + PIK3CA N1044K (1)
PIK3CA P449T (1)
PIK3CA Q546 (1)
PIK3CA Q546K (1)
PIK3CA R38C (1)
PIK3CA V955G (1)
PIK3CA mutation + AKT1 mutation + PTEN mutation (1)
PIK3CA mutation + EP300 mutation (1)
PIK3CA mutation + ER mutation (1)
PIK3CA mutation + FGFR2 rearrangement (1)
PIK3CA mutation + HRAS mutation (1)
PIK3CA mutation + PTEN mutation + KRAS mutation (1)
PIK3CA mutation + TERT promoter mutation (1)
PIK3CA mutation + TTN mutation + IDH2 mutation (1)
PIK3CA wild-type + KRAS wild-type (1)
PIK3CA wild-type + PTEN wild-type (1)
PIK3CA Q546R (1)
HER-2 negative + HR positive + PIK3CA exon 20 mutation (0)
HER-2 negative + HR positive + PIK3CA exon 7 mutation (0)
HER-2 negative + HR positive + PIK3CA exon 9 mutation (0)
HER-2 negative + HR positive + PIK3CA mutation (0)
PIK3CA G542L (0)
PIK3CA mutation (108)
PIK3CA E545K (26)
PIK3CA E542K (10)
BRAF V600E + PIK3CA mutation (4)
EGFR mutation + PIK3CA mutation (4)
PIK3CA E545 (4)
PIK3CA H1047 (4)
PIK3CA K111N (4)
PIK3CA E542 (3)
PIK3CA E546 (3)
PIK3CA H1047L (3)
PIK3CA M1043I (3)
PIK3CA mutation + PTEN mutation (3)
PIK3CA wild-type (3)
EGFR T790M + PIK3CA H1047R (2)
ER negative + PIK3CA H1047R (2)
HER-2 V777L + PIK3CA H1047R (2)
PIK3CA C420R (2)
PIK3CA E545A (2)
PIK3CA N345K (2)
PIK3CA Q75E (2)
PIK3CA mutation + ESR1 mutation (2)
PIK3CA mutation + KRAS mutation (2)
TP53 T175H + PIK3CA H1047R (2)
TP53 mutation + PIK3CA mutation + CD74 mutation (2)
ALK rearrangement + PIK3CA mutation (1)
ALK rearrangement + TP53 R175H + EGFR A839V + PI3KCA mutation (1)
EGFR L858R + PIK3CA H1047R + PIK3CA E545K (1)
EGFR T790M + PIK3CA Mutation (1)
EGFR exon 19 mutation + EGFR C797S + PIK3CA mutation (1)
HR positive + PIK3CA H1047R (1)
HR positive + PIK3CA H1047R + ER D538G (1)
HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G (1)
IDH1 R132C + PIK3CA E545K + IDH2 R172K (1)
PIK3CA D350G (1)
PIK3CA E110K (1)
PIK3CA E453K (1)
PIK3CA E542Q (1)
PIK3CA E545G (1)
PIK3CA E545X (1)
PIK3CA G1049R (1)
PIK3CA G1049R + AKT1 E17K (1)
PIK3CA G106_108del (1)
PIK3CA H1047R + PIK3CA D959N + ER E380Q (1)
PIK3CA H1047X (1)
PIK3CA I391M (1)
PIK3CA K944N (1)
PIK3CA K966E (1)
PIK3CA N345K + PIK3CA N1044K (1)
PIK3CA P449T (1)
PIK3CA Q546 (1)
PIK3CA Q546K (1)
PIK3CA R38C (1)
PIK3CA V955G (1)
PIK3CA mutation + AKT1 mutation + PTEN mutation (1)
PIK3CA mutation + EP300 mutation (1)
PIK3CA mutation + ER mutation (1)
PIK3CA mutation + FGFR2 rearrangement (1)
PIK3CA mutation + HRAS mutation (1)
PIK3CA mutation + PTEN mutation + KRAS mutation (1)
PIK3CA mutation + TERT promoter mutation (1)
PIK3CA mutation + TTN mutation + IDH2 mutation (1)
PIK3CA wild-type + KRAS wild-type (1)
PIK3CA wild-type + PTEN wild-type (1)
PIK3CA Q546R (1)
HER-2 negative + HR positive + PIK3CA exon 20 mutation (0)
HER-2 negative + HR positive + PIK3CA exon 7 mutation (0)
HER-2 negative + HR positive + PIK3CA exon 9 mutation (0)
HER-2 negative + HR positive + PIK3CA mutation (0)
PIK3CA G542L (0)
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® Liquid CDx (21)
therascreen® PIK3CA RGQ PCR Kit (3)
FoundationOne® CDx (110)
FoundationOne® Liquid CDx (21)
therascreen® PIK3CA RGQ PCR Kit (3)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PIK3CA H1047R
Breast Cancer
PIK3CA H1047R
Breast Cancer
alpelisib
Sensitive: C2 – Inclusion Criteria
alpelisib
Sensitive
:
C2
alpelisib
Sensitive: C2 – Inclusion Criteria
alpelisib
Sensitive
:
C2
PIK3CA H1047R
Colorectal Cancer
PIK3CA H1047R
Colorectal Cancer
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
PIK3CA H1047R
HER2 Positive Breast Cancer
PIK3CA H1047R
HER2 Positive Breast Cancer
PF-05212384 + trastuzumab-pkrb
Sensitive: C3 – Early Trials
PF-05212384 + trastuzumab-pkrb
Sensitive
:
C3
PF-05212384 + trastuzumab-pkrb
Sensitive: C3 – Early Trials
PF-05212384 + trastuzumab-pkrb
Sensitive
:
C3
PIK3CA H1047R
Non Small Cell Lung Cancer
PIK3CA H1047R
Non Small Cell Lung Cancer
trametinib + dabrafenib
Sensitive: C3 – Early Trials
trametinib + dabrafenib
Sensitive
:
C3
trametinib + dabrafenib
Sensitive: C3 – Early Trials
trametinib + dabrafenib
Sensitive
:
C3
PIK3CA H1047R
Breast Cancer
PIK3CA H1047R
Breast Cancer
TAS-117
Sensitive: C3 – Early Trials
TAS-117
Sensitive
:
C3
TAS-117
Sensitive: C3 – Early Trials
TAS-117
Sensitive
:
C3
PIK3CA H1047R
Hormone Receptor Positive Breast Cancer
PIK3CA H1047R
Hormone Receptor Positive Breast Cancer
everolimus
Sensitive: C3 – Early Trials
everolimus
Sensitive
:
C3
everolimus
Sensitive: C3 – Early Trials
everolimus
Sensitive
:
C3
PIK3CA H1047R
Melanoma
PIK3CA H1047R
Melanoma
dabrafenib
Sensitive: C4 – Case Studies
dabrafenib
Sensitive
:
C4
dabrafenib
Sensitive: C4 – Case Studies
dabrafenib
Sensitive
:
C4
PIK3CA H1047R
HER2 Positive Breast Cancer
PIK3CA H1047R
HER2 Positive Breast Cancer
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib + everolimus
Sensitive: C4 – Case Studies
trametinib + dabrafenib + everolimus
Sensitive
:
C4
trametinib + dabrafenib + everolimus
Sensitive: C4 – Case Studies
trametinib + dabrafenib + everolimus
Sensitive
:
C4
PIK3CA H1047R
Salivary Gland Cancer
PIK3CA H1047R
Salivary Gland Cancer
vandetanib
Sensitive: C4 – Case Studies
vandetanib
Sensitive
:
C4
vandetanib
Sensitive: C4 – Case Studies
vandetanib
Sensitive
:
C4
PIK3CA H1047R
Colon Cancer
PIK3CA H1047R
Colon Cancer
PF-05212384
Sensitive: D – Preclinical
PF-05212384
Sensitive
:
D
PF-05212384
Sensitive: D – Preclinical
PF-05212384
Sensitive
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
trametinib
Sensitive: D – Preclinical
trametinib
Sensitive
:
D
trametinib
Sensitive: D – Preclinical
trametinib
Sensitive
:
D
PIK3CA H1047R
Endometrial Cancer
PIK3CA H1047R
Endometrial Cancer
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
PIK3CA H1047R
Colorectal Cancer
PIK3CA H1047R
Colorectal Cancer
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
PIK3CA H1047R
Breast Cancer
PIK3CA H1047R
Breast Cancer
trastuzumab + lapatinib
Resistant: D – Preclinical
trastuzumab + lapatinib
Resistant
:
D
trastuzumab + lapatinib
Resistant: D – Preclinical
trastuzumab + lapatinib
Resistant
:
D
PIK3CA H1047R
Breast Cancer
PIK3CA H1047R
Breast Cancer
trastuzumab + MEN1611
Sensitive: D – Preclinical
trastuzumab + MEN1611
Sensitive
:
D
trastuzumab + MEN1611
Sensitive: D – Preclinical
trastuzumab + MEN1611
Sensitive
:
D
PIK3CA H1047R
Breast Cancer
PIK3CA H1047R
Breast Cancer
GDC-0941
Sensitive: D – Preclinical
GDC-0941
Sensitive
:
D
GDC-0941
Sensitive: D – Preclinical
GDC-0941
Sensitive
:
D
PIK3CA H1047R
HER2 Positive Breast Cancer
PIK3CA H1047R
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: D – Preclinical
ado-trastuzumab emtansine
Sensitive
:
D
ado-trastuzumab emtansine
Sensitive: D – Preclinical
ado-trastuzumab emtansine
Sensitive
:
D
PIK3CA H1047R
Head and Neck Cancer
PIK3CA H1047R
Head and Neck Cancer
alpelisib
Sensitive: D – Preclinical
alpelisib
Sensitive
:
D
alpelisib
Sensitive: D – Preclinical
alpelisib
Sensitive
:
D
PIK3CA H1047R
Ovarian Cancer
PIK3CA H1047R
Ovarian Cancer
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
PIK3CA H1047R
Ovarian Cancer
PIK3CA H1047R
Ovarian Cancer
LX-086
Sensitive: D – Preclinical
LX-086
Sensitive
:
D
LX-086
Sensitive: D – Preclinical
LX-086
Sensitive
:
D
PIK3CA H1047R
Head and Neck Cancer
PIK3CA H1047R
Head and Neck Cancer
SHR-A1307
Sensitive: D – Preclinical
SHR-A1307
Sensitive
:
D
SHR-A1307
Sensitive: D – Preclinical
SHR-A1307
Sensitive
:
D
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
PIK3CA H1047R
HER2 Negative Breast Cancer
PIK3CA H1047R
HER2 Negative Breast Cancer
LX-086
Sensitive: D – Preclinical
LX-086
Sensitive
:
D
LX-086
Sensitive: D – Preclinical
LX-086
Sensitive
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
GDC-0941
Resistant: D – Preclinical
GDC-0941
Resistant
:
D
GDC-0941
Resistant: D – Preclinical
GDC-0941
Resistant
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
BMS-722782
Resistant: D – Preclinical
BMS-722782
Resistant
:
D
BMS-722782
Resistant: D – Preclinical
BMS-722782
Resistant
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PF-3845
Resistant: D – Preclinical
PF-3845
Resistant
:
D
PF-3845
Resistant: D – Preclinical
PF-3845
Resistant
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PF-05212384
Sensitive: D – Preclinical
PF-05212384
Sensitive
:
D
PF-05212384
Sensitive: D – Preclinical
PF-05212384
Sensitive
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
cetuximab
Resistant: D – Preclinical
cetuximab
Resistant
:
D
cetuximab
Resistant: D – Preclinical
cetuximab
Resistant
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
RTB101
Sensitive: D – Preclinical
RTB101
Sensitive
:
D
RTB101
Sensitive: D – Preclinical
RTB101
Sensitive
:
D
PIK3CA H1047R
Thyroid Gland Carcinoma
PIK3CA H1047R
Thyroid Gland Carcinoma
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
temsirolimus + BAY86-9766
Sensitive
:
D
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
temsirolimus + BAY86-9766
Sensitive
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
GDC-0032
Sensitive: D – Preclinical
GDC-0032
Sensitive
:
D
GDC-0032
Sensitive: D – Preclinical
GDC-0032
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login